Rhythm Pharmaceuticals (RYTM) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 24, 2026, at 2:00 PM ET, conducted virtually via live webcast.

• Proxy materials and 2025 Annual Report are available online for review and voting.

• Shareholders are encouraged to access materials electronically to support environmental initiatives.

Voting matters and shareholder proposals

• Election of two Class III directors, David W.J. McGirr and David P. Meeker, M.D., for three-year terms until the 2029 annual meeting.

• Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Advisory (non-binding) vote on the compensation of named executive officers.

Board of directors and corporate governance

• Board recommends voting FOR all director nominees and FOR both other proposals.